Prosecution Insights
Last updated: October 04, 2026

Kramer & Amado, P.C.

Technology area: Biotechnology & Pharmaceuticals

13 pending office actions • 10 clients • 12 examiners • 11 art units • 0 of 13 (0%) have an AI response strategy ready

Analysis

KRAMER & AMADO, P.C. operates in the Biotechnology & Pharmaceuticals technology area, having managed 870 career applications. The firm has established a resolved allowance rate of 80.88 percent, which reflects the proportion of its applications that reach a grant. This record of 870 career applications serves as the basis for the firm's experience in the life sciences sector.

The firm's prosecution process involves an average of 3.83 office actions per allowance. This metric indicates the typical number of interactions between the firm and patent examiners before an application reaches an allowance. Currently, the firm is addressing 16 pending office actions, representing its active engagement in the Biotechnology & Pharmaceuticals sector. These 16 pending office actions are fewer than the 870 career applications on record.

With 870 career applications and an 80.88 percent allowance rate, the firm has a historical record of performance. The 3.83 office actions per allowance provide a benchmark for the expected duration of the prosecution cycle. The 16 pending office actions show the firm's continued focus on its clients' intellectual property objectives in the biotech space.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Quality Metrics (n=870 apps, methodology: how we score firms)

80.9%
Allowance Rate
n=870
+0.77σ
Allowance Rate (norm)
n=870
3.8
OAs to Allowance
n=605
-0.02σ
OAs to Allow (norm)
n=605
1134 days
Time to Allowance
n=605
+13.8pp
Interview Lift
n=870
25.0%
RCE Rate
n=870
2.6%
Appeal Rate
n=870

Rejection Performance (% of received rejections ultimately overcome)

85.4%
§101 Overcome
n=89
76.6%
§102 Overcome
n=214
80.0%
§103 Overcome
n=429
83.2%
§112 Overcome
n=333

Specialization & Scale

A61K, A61P, H04L
Top CPC Subclasses
27%
Top-3 CPC Share
n=870
6
Practitioners
n=870
145.0
Apps / Practitioner
n=870

Portfolio Summary

13
Total Pending OAs
6
Non-Final OAs
7
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

4
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
1
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (4)Due later (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

7
Hard (54%)
5
Medium (38%)
1
Easy (8%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§101 + other1 (8%)
§103 only4 (31%)
§102 only1 (8%)
§112 only1 (8%)
Multi-statute (no §101)6 (46%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

11
Life Sciences
85% of docket
1
Information Tech
8% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
1
Mechanical / Eng
8% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

130 h
Manual time on pending OAs
26 h
Time saved (low, 20%)
46 h
Time saved (mid, 35%)
1.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
MACFARLANE, STACEY NEE 2 53.5% +39.6%
HUNTER, MISHAWN N 1 78.2% +14.3%
VALLE, ERNESTO 1 65.8% +32.9%
PEEBLES, KATHERINE 1 35.5% +48.6%
BAZARGANI, ARYA AHMADI 1 62.5% +31.3%
GONZALEZ, LUISALBERTO 1 59.4% +47.2%
SPAINE, ROBERT FRANKLIN 1 75.0% +0.0%
BOECKELMAN, JACOB A 1 35.2% +45.6%
ADDIE, RAYMOND W 1 81.1% +8.5%
WRIGHT, PATRICIA KATHRYN 1 65.3% +42.6%

Quick Wins (1)

Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
17507961 ROAD PLATE MOVING SYSTEM AND METHOD ADDIE, RAYMOND W 15d overdue

Hard Cases (7)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.

App #TitleExaminerDue in
18054285 Compositions Comprising Human Skin Fibroblasts and Amyloid Beta Peptide MACFARLANE, STACEY NEE 70d overdue
19456751 INTERACTIVE SAFETY SYSTEM FOR VEHICLES HUNTER, MISHAWN N —
18547025 AN EFLORNITHINE COMPOSITION FOR INHIBITING HAIR GROWTH PEEBLES, KATHERINE —
18547044 NON-AQUEOUS INJECTABLE COMPOSITION OR SUSTAINED RELEASE OF BUPRENORPHINE AND USE THEREOF BAZARGANI, ARYA AHMADI —
18256295 BIO PESTICIDAL COMPOSITION CONTAINS NOVEL NONANOATE ESTERS OF SUGARS AND SUGAR ALCOHOLS TO CONTROL LEPIDOPTERA, HEMIPTERA AND THYSANOPTERA INSECTS GONZALEZ, LUISALBERTO —
17905564 SYNERGISTIC COMPOSITIONS FOR IMPROVING BRAIN HEALTH SPAINE, ROBERT FRANKLIN —
17048485 CELL SEPARATION CHAMBER AND CELL SEPARATION SYSTEM AND METHOD MARCHESCHI, MICHAEL A —

Interview Candidates (9)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
17066961 FIBROBLAST GROWTH PATTERNS FOR DIAGNOSIS OF ALZHEIMER'S DISEASE MACFARLANE, STACEY NEE 74d overdue
18054285 Compositions Comprising Human Skin Fibroblasts and Amyloid Beta Peptide MACFARLANE, STACEY NEE 70d overdue
17554636 COMPOSITION FOR ENHANCEMENT OF BIOAVAILABILITY OF PHYTOCHEMICALS AND PROCESS FOR PREPARATION THEREOF BOECKELMAN, JACOB A 5d overdue
19456751 INTERACTIVE SAFETY SYSTEM FOR VEHICLES HUNTER, MISHAWN N —
18548691 SOLID STATE FORMS OF 2-(3,5-DICHLOROPHENYL)-1,3-BENZOXAZOLE-6-CARBOXYLIC ACID OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS AND POLYMORPHS THEREOF VALLE, ERNESTO —
18547025 AN EFLORNITHINE COMPOSITION FOR INHIBITING HAIR GROWTH PEEBLES, KATHERINE —
18547044 NON-AQUEOUS INJECTABLE COMPOSITION OR SUSTAINED RELEASE OF BUPRENORPHINE AND USE THEREOF BAZARGANI, ARYA AHMADI —
18256295 BIO PESTICIDAL COMPOSITION CONTAINS NOVEL NONANOATE ESTERS OF SUGARS AND SUGAR ALCOHOLS TO CONTROL LEPIDOPTERA, HEMIPTERA AND THYSANOPTERA INSECTS GONZALEZ, LUISALBERTO —

Client Portfolio (10 clients)

Top Art Units

Art UnitApps
16752
16552
24841
16231
16171
16131
16241
36711
17981
17961

Pending Office Actions

App #TitleClientExaminerArt UnitStatutesStatusDue inAIFiled
19456751 INTERACTIVE SAFETY SYSTEM FOR VEHICLES Libre Holdings Inc. HUNTER, MISHAWN N 2484 §102§103§112 Non-Final OA — Pending Jan 22, 2026
18548691 SOLID STATE FORMS OF 2-(3,5-DICHLOROPHENYL)-1,3-BENZOXAZOLE-6-CARBOXYLIC ACID OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS AND POLYMORPHS THEREOF Cipla Limited VALLE, ERNESTO 1623 §112 Final Rejection — Pending Sep 01, 2023
18547025 AN EFLORNITHINE COMPOSITION FOR INHIBITING HAIR GROWTH Navin Saxena Research And Technology Private Limited PEEBLES, KATHERINE 1617 §103§112 Non-Final OA — Pending Aug 18, 2023
18547044 NON-AQUEOUS INJECTABLE COMPOSITION OR SUSTAINED RELEASE OF BUPRENORPHINE AND USE THEREOF Navin Saxena Research And Technology Private Limited BAZARGANI, ARYA AHMADI 1613 §103§112 Final Rejection — Pending Aug 18, 2023
18256295 BIO PESTICIDAL COMPOSITION CONTAINS NOVEL NONANOATE ESTERS OF SUGARS AND SUGAR ALCOHOLS TO CONTROL LEPIDOPTERA, HEMIPTERA AND THYSANOPTERA INSECTS Fertis India Pvt. Ltd. GONZALEZ, LUISALBERTO 1624 §103§112 Non-Final OA — Pending Jun 07, 2023
18054285 Compositions Comprising Human Skin Fibroblasts and Amyloid Beta Peptide West Virginia University MACFARLANE, STACEY NEE 1675 §102§103 Final Rejection 70d overdue Pending Nov 10, 2022
17905564 SYNERGISTIC COMPOSITIONS FOR IMPROVING BRAIN HEALTH Laila Nutrceuticals SPAINE, ROBERT FRANKLIN 1655 §101§103§112Other Non-Final OA — Pending Sep 02, 2022
17554636 COMPOSITION FOR ENHANCEMENT OF BIOAVAILABILITY OF PHYTOCHEMICALS AND PROCESS FOR PREPARATION THEREOF Olene Life Sciences Private Limited BOECKELMAN, JACOB A 1655 §103 Non-Final OA 5d overdue Pending Dec 17, 2021
17507961 ROAD PLATE MOVING SYSTEM AND METHOD Fer-Pal Construction, Ltd. ADDIE, RAYMOND W 3671 §103 Non-Final OA 15d overdue Pending Oct 22, 2021
17048766 DISPOSABLE CARTRIDGE COOPERATING WITH A PLATFORM IN A FLEXIBLE SYSTEM FOR HANDLING AND/OR MANIPULATING FLUIDS Aglaris Ltd. WRIGHT, PATRICIA KATHRYN 1798 §103 Final Rejection — Pending Oct 19, 2020
17048485 CELL SEPARATION CHAMBER AND CELL SEPARATION SYSTEM AND METHOD Aglaris Ltd. MARCHESCHI, MICHAEL A 1796 §103§112 Final Rejection — Pending Oct 16, 2020
17066961 FIBROBLAST GROWTH PATTERNS FOR DIAGNOSIS OF ALZHEIMER'S DISEASE West Virginia University MACFARLANE, STACEY NEE 1675 §103 Final Rejection 74d overdue Pending Oct 09, 2020
15107152 CONVERGENCE OF AGGREGATION RATE WITH VALIDATED PERIPHERAL DIAGNOSTIC FOR ALZHEIMER'S DISEASE West Virginia University NGUYEN, NGHI V 1653 §102 Final Rejection 69d Pending Jun 22, 2016

Managing Kramer & Amado, P.C.'s Patent Prosecution?

IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month